Pharmacological intervention at ionotropic glutamate receptor complexes

Current Pharmaceutical Design

Volumn 12, Issue 28, 2006, Pages 3583-3596

  Planells Cases, Rosa ^a   Lerma, Juan ^b   Ferrer Montiel, Antonio ^c  

^a CENTRO DE INVESTIGACIÓN PRÍNCIPE FELIPE   (Spain)

^b INSTITUTO DE NEUROCIENCIAS   (Spain)

^c MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

Author keywords

AMPA receptor; Kainate receptors; Neurodegeneration; NMDA antagonist; NR2A subunits; YM872

Indexed keywords

6 CYANO 7 NITRO 2,3 QUINOXALINEDIONE; 6,7 DINITRO 2,3 QUINOXALINEDIONE; [1,2,3,4 TETRAHYDRO 7 (1H IMIDAZOL 1 YL) 6 NITRO 2,3 DIOXO 1 QUINOXALINYL]ACETIC ACID; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; AMPA RECEPTOR; AMPA RECEPTOR AGONIST; AMPA RECEPTOR ANTAGONIST; ANIRACETAM; BENZAMIDE DERIVATIVE; BENZODIAZEPINE DERIVATIVE; BENZOTHIADIAZINE DERIVATIVE; CYCLOTHIAZIDE; EXCITOTOXIN; GLUTAMIC ACID; GLYCINE RECEPTOR ANTAGONIST; IONOTROPIC RECEPTOR; KAINIC ACID; KAINIC ACID RECEPTOR; KAINIC ACID RECEPTOR AGONIST; KAINIC ACID RECEPTOR ANTAGONIST; KETAMINE; MEMANTINE; METABOTROPIC RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NAMEDA; NEUROTRANSMITTER; PHTHALAZINE DERIVATIVE; QUINAZOLINONE DERIVATIVE; SULFONAMIDE; UNINDEXED DRUG;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; CLINICAL TRIAL; CONFUSION; DEGENERATIVE DISEASE; DIZZINESS; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; HALLUCINATION; HEADACHE; HUMAN; HUNTINGTON CHOREA; KIDNEY NECROSIS; NERVE CELL NECROSIS; NEUROPATHIC PAIN; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RECEPTOR INTRINSIC ACTIVITY; REVIEW; SIGNAL TRANSDUCTION; STROKE;

EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; RECEPTORS, AMPA; RECEPTORS, KAINIC ACID; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 33749441653     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206778522092     Document Type: Review

References (131)

1. Clements JD, Lester RA, Tong G, Jahr CE, Westbrook GL. The time course of glutamate in the synaptic cleft. Science 2000; 258: 1498-1501.
2. Pin JP, Galvez T, Prezeau L. Evolution, structure, and activation mechanism of family 3/C G-protein coupled receptors. Pharmacol Ther 2003; 98: 325-54.
3. Swanson CJ, Bures M, Johnson MP, Linden AM, Monn JA, Schoepp DD. Metabotropic glutamate receptors as novel targets for anxiety and stress disorders. Nat Rev Drug Discov 2005; 4: 131-44.
4. Zhu L, Strata P, Andjus PR. Pharmacology of the metabotropic glutamate receptor mediated current at the climbing fiber to Purkinje cell synapse. Prog Brain Res 2005; 148: 299-06.
5. Dingledine R, Borges K, Bowie D, Traynelis SF. The glutamate receptor ion family. Pharmacol Rev 1999; 51: 7-61.
6. Lam HM, Chiu J, Hsieh MH, Meisel L, Oliveira IC, Shin M, et al. Glutamate-receptor genes in plants. Nature 1998; 396: 125-6.
7. Nahm WK, Philpot BD, Adams MM, Badiavas EV, Zhou LH, Butmarc J, et al. Significance of N-methyl-D-aspartate (NMDA receptor-mediated signalling in human keratinocytes. J Cell Physiol 2004; 200: 309-17.
8. Wollmuth LP, Sobolevsky AI. Structure and gating of the glutamate receptor ion channel. Trends Neurosci 2004; 27: 321-8.
9. Chen G-Q, Cui C, Mayer ML, Gouaux E. Functional characterization of a potassium-selective prokaryotic glutamate receptor. Nature 1999; 402: 817-821.
10. Künig G, Niedermeyer B, Deckert J, Gsell W, Ransmayr G, Riederer P. [3H]α-amino-3-hydroxy-5-methyl4-isoxazole-propionic acid (AMPA) binding by the anticonvulsant valproate in clinically relevant concentrations: An autoradiographic investigation in human hippocampus. Epilepsy Res 1998; 31: 153-157.
11. Hollmann M and Heinemann S. Cloned glutamate receptors. Annu Rev Neurosci 1994; 17: 31-108.
12. Martin LJ, Blackstone CD, Levey AI, Huganir RL, Price DL. AMPA glutamate receptor subunits are differentially distributed in rat brain. Neuroscience 1993; 53: 327-58.
13. Shi S-H, Hayashi Y, Petralia RS, Zaman SH, Wenthold RJ, Svoboda K, et al. Rapid spine delivery and redistribution of AMPA receptors after synaptic NMDA receptor activation. Science 1999; 284: 1811-1816.
14. Shi S-H, Hayashi Y, Esteban JA, Malinow, R. Subunit-specific rules governing AMPA receptor trafficking to synapses in hippocampal pyramidal neurons. Cell 2001; 105: 331-343.
15. Hayashi Y, Shi SH, Esteban JA, Poncer JC, Malinow R. Driving AMPA receptors into synapses by LTP and CaMKII: requirement for GluR1 and PDZ domain interaction. Science 2000; 287: 2262-2267.
16. Passafaro M, Piech V, Sheng, M. Subunit-specific temporal and spatial patterns of AMPA receptor exocytosis in hippocampal neurons. Nat Neurosci 2001; 4: 917-926.
17. Wenthold RJ, Petralia RS, Blahos J II, Niedzielski AS. Evidence for multiple AMPA receptor complexes in hippocampal CA1/CA2 neurons. J Neurosci 1996; 16: 1982-1989.
18. 2+ permeability in single rat retinal ganglion cells. Neuroscience 1995; 67: 177-188.
19. Washburn MS, Numberger M, Zhang S, Dingledine R. Differential dependence on GluR2 expression of three characteristic features of AMPA receptors. J Neurosci 1997; 17: 9393-940.
20. Tóth K, McBain C. Afferent-specific innervation of two distinct AMPA receptor subtypes on single hippocampal interneurons. Nat Neurosci 1998; 1: 572-577.
21. Jia Z, Agopyan N, Miu P, Xiong Z, Henderson J, Gerlai R, et al. Enhanced LTP in mice deficient in the AMPAR GluR2. Neuron 1996; 17: 945-956.
22. Bowie D, Mayer ML. Inward rectification of both AMPA and kainate subtype glutamate receptors generated by polyamine-mediated ion channel block. Neuron 1995; 15: 453-462.
23. Seeburg PH, Hartner J. Regulation of ion channel/neurotransmitter receptor function by RNA editing. Curr Opin Neurobiol 2003; 13: 279-83.
24. Brusa R, Zimmermann F, Koh D-S, Feldmeyer D, Gass P, Seeburg PH, et al. Early-onset epilepsy and postnatal lethality associated with an editing-deficient GluR-B allele in mice. Science 1995; 270: 1677-1680.
25. Kwak S, Kawahara Y. Deficient RNA editing of GluR2 and neuronal death in amyotropic lateral sclerosis. J Mol Med 2005; 93: 110-20.
26. Zamanillo D, Sprengel R, Hvalby O, Jensen V, Burnashev N, Rozov A, et al. Importance of AMPA receptors for hippocampal synaptic plasticity but not for spatial learning. Science 1999; 284: 1805-1811.
27. Reisel D, Bannerman DM, Schmitt WB, Deacon RM, Fint J, Borchardt T, et al. Spatial memory dissociations in mice lacking GluR1. Nat Neurosci 2002; 5: 868-73.
28. Schmitt WB, Deacon RM, Seeburg PH, Rawlins JN, Bannerman DM. A within-subjects, within-task demonstration of intact spatial reference memory and impaired spatial working memory in glutamate receptor-A-deficient mice. J Neurosci 2003; 23: 3953-9.
29. Meng Y, Zhang Y and Jia Z. Synaptic Transmission and Plasticity in the Absence of AMPA Glutamate Receptor GluR2 and GluR3. Neuron 2003; 39: 163-176.
30. Knapp AG, Schmidt KF, Dowling JE. Dopamine modulates the kinetics of ion channels by excitatory amino acids in retinal horizontal cells. Proc Natl Acad Sci USA 1990; 87: 767-771.
31. Banke T, Traynelis S Control of GluR1 activation by cAMP dependent protein kinase. Abstr Soc Neurosci 1998; 2: 1272.
32. Lee HK, Takimaya K, Hans JS, Man H, Kim CH, Rumbaugh G, et al. Phosphorylation of the AMPA receptor GluR1 subunit is required for synaptic plasticity and retention of spatial memory. Cell 2003; 112: 613-643.
33. Barria A, Derkach V, Soderling T. Identification of the Ca2+/calmodulin dependent protein kinase II regulatory phosphorylation site of the α-amino-3-hydroxyl-5-methyl-isoxazole-propionate type glutamate receptor. J Biol Chem 1997; 272: 32727-32730.
34. Roche KW, O'Brien RJ, Mammen AL, Bernhardt J, Huganir RL. Characterization of multiple phosphorylation sites on the AMPA receptor GluR1 subunit. Neuron 1996; 16: 1179-1188.
35. Barria A, Muller D, Derkach V, Griffith LC, Soderling T. Regulatory phosphorylation of AMPA-type glutamate recptors by CaMKII during long term potentiation. Science 1997; 276: 2042-2045.
36. Dong H, O'Brien RJ, Fung ET, Lanahan AA, Worley PF, Huganir RL. GRIP: A synaptic PDZ domain-containing protein that interacts with AMPA receptors. Nature 1997; 386: 279-284.
37. Srivastava S, Osten P, Vilim FS, Khatri L, Inman G, Statees B, et al. Novel Anchorage of GluR2/3 to the postsynaptic density by the AMPA receptor-binding protein ABP. Neuron 1998; 21: 581-591.
38. Xia J, Staudinger JL, Zhang S, Huganir RL. Interaction of AMPA receptors with Pick1. Soc Neurosci Abstr 1998; 24: 842.
39. Nishimune A, Isaac JTR, Molnar E, Noel J, Nash SR, Tagaya M, et al. NSF binding to GluR2 regulates synaptic transmission. Neuron 1998; 21: 87-97.
40. Song I, Kamboj S, Xia J, Dong H, Liao D, Huganir RL. Interaction of the N-ethylmaleimide-sensitive factor with AMPA receptors. Neuron 1998; 21: 393-400.
41. Rosenmund C, Carr DW, Bergeson SE, Nilayer G, Scott JD, Westbrook GL. Anchoring of protein kinase A is required for modulation of AMPA/kainate receptors on hippocampal neurons. Nature 1994; 368: 853-856.
42. Chen L, Chetkovich DM, Petralia RS, Sweeney NT, Kawasaki Y, Wenthold RJ, et al. Stargazin regulates synaptic targeting of AMPA receptors by two distinct mechanisms. Nature 2000; 408: 936-943.
43. Tomita S, Adesnik H, Sekiguchi M, Zhang W, Wada K, Howe JR, et al. Stargazin modulates AMPA receptor gating and trafficking by distinct domains. Nature 2005; 435: 1052-8.
44. Hashimoto K, Fukaya M, Qiao X, Sakimura K, Watanabe M and Kano. Impairment of AMPA receptor function in cerebellar granule cells of ataxic mutant mouse stargazer. J Neurosci 1999; 19: 6027-6036.
45. Kew JN, Kemp JA. Ionotropic and metabotropic glutamate receptor structure and pharmacology. Psychopharmacology 2005; 179: 4-29.
46. Mayer ML, Armstrong N. Structure and function of glutamate receptor ion channels. Annu Rev Physiol 2004; 66: 161-181.
47. O'Neill MJ, Bleakman D, Zimmerman DM, Nisenbaum ES. AMPA receptor potentiators for the treatment of CNS disorders. Curr Drug Targets CNS Neurol Disord 2004; 3: 181-94.
48. Danysz W. CX-516 Cortex pharmaceuticals. Curr Opin Investig Drugs 2002; 3: 1081-8.
49. Turski L, Huth A, Sheardown M, McDonald F, Neuhaus R, Schneider H, et al. ZK200775: A phosphonate quinoxalinedione/(AMPA) antagonist for neuroprotection in stroke and trauma. Proc Natl Acad Sci USA 1998; 95: 10960-10965.
50. Terai K, Suzuki M, Sasanata M, Yatsugi S, Yamaguchi T, Miyata K. Effect of AMPA receptor antagonist YM872 on cerebral hematoma size and neurological recovery in the intracerebral hemorrhage rat model. Eur J Pharmacol 2003; 467: 95-101.
51. Elting JW, Sulter GA, Kaste M, Lees KR, Diener HC, Hommel M, et al. AMPA antagonist ZK200775 in patients with acute ischemic stroke: possible glial cell toxicity detected by monitoring of S-100B serum levels. Stroke 2002; 33: 2813-8.
52. Langan YM, Lucas R, Jewell H, Toublanc N, Schaefer H, Sandr JW, et al. Talampanel, a new anti-epileptic drug: single and multiple-dose pharmacokinetics and initial 1-week experience with patients with chronic intractable epilepsy. Epilepsia 2003; 44: 46-53.
53. Menniti FS, Buchan AM, Chenard BL, Critchett DJ, Ganong AH, Guanowsky V, et al. CP-465, 022 a selective noncompetitive AMPA receptor antagonist blocks AMPA receptor but is not neuroprotective in vivo. Stroke 2003; 34:171-6.
54. Strømgaard K, Mellor I. AMPA receptor ligands: Synthetic and pharmacological studies of polyamines and polyamine toxins. Med Res Rev 2004; 24: 689-720.
55. Lerma J. Roles and rules of kainate receptors in synaptic transmission. Nat Rev Neurosci 2003; 4: 481-95.
56. Bettler B, Boulter J, Hermans-Borgmeyer I, O'Shea-Greenfield A, Deneris ES, Moll C, et al. Cloning of a novel glutamate receptor subunit, GluR5: expression in the nervous system during development. Neuron 1990; 5: 583-595.
57. Sommer B, Burnashev N, Verdoorn TA, Keinänen K, Sakmann B, Seeburg PH. A glutamate receptor channel with high affinity for domoate and kainate. EMBO J 1992; 11: 1651-1656.
58. Egebjerg J, Bettler B, Hermans-Borgmeyer I, Heinemann SF. Cloning of a cDNA for a glutamate receptor subunit activated by kainate but not by AMPA. Nature 1991; 351: 745-748.
59. Herb A, Burnashev N, Werner P, Sakmann B, Wisden W, Seeburg PH. The KA-2 subunit of excitatory amino acid receptors shows widespread expression in brain and forms ion channels with distantly related subunits. Neuron 1992; 8: 775-785.
60. Schiffer HH, Swanson GT, Heinemann SF. Rat GluR7 and a carboxy-terminal splice variant, GluR7b, are functional kainate receptor subunits with a low sensitivity to glutamate. Neuron 1997; 19: 1141-1146.
61. Paternain AV, Herrera MT, Nieto MA, Lerma J. GluR5 and GluR6 kainate receptor subunits coexist in hippocampal neurons and coassemble to form functional receptors. J Neurosci 2000; 20: 196-205.
62. Cui C, Mayer ML. Heteromeric kainate receptors formed by the coassembly of GluR5, GluR6, and GluR7. J Neurosci 1999; 19: 8281-91.
63. Lerma J, Paternain AV, Naranjo JR, Mellstrom B. Functional kainate-selective glutamate receptors in cultured hippocampal neurons. Proc Natl Acad Sci USA 1993; 90: 11688-92.
64. Wong LA Mayer ML, Jane DE, Watkins JC. Willardines differentiate agonist binding sites for kainate- versus AMPA-preferring glutamate receptors in DRG and hippocampal neurons. J Neurosci 1994; 14: 3881-3897.
65. Honoré T, Davies SN, Drejer J, Fletcher EJ, Jacobsen P, Lodge D, et al. Quinoxalinediones: potent competitive non-NMDA glutamate receptor antagonists. Science 1998; 241: 701-703.
66. Paternain AV, Vicente MA, Nielsen EØ, Lerma J. Comparative antagonism of kainate-activated AMPA and kainate receptors in hippocampal neurons. Eur J Neurosci 1996; 8: 2129-2136.
67. Wilding TJ, Huettner JE. Differential antagonism of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-preferring and kainate-preferring receptors by 2, 3-benzodiazepines. Mol Pharmacol 1995; 47: 582-587.
68. Mulle C, Sailer A, Swanson GT, Brana C, O'Gorman S, Bettler B, et al. Subunit composition of kainate receptors in hippocampal interneurons. Neuron 2000; 28: 475-84.
69. Lerma J, Morales M, Vicente MA, and Herreras O. Glutamate receptors of the kainate type and synaptic transmission. Trends Neurosci 1997; 20: 9-12.
70. Paternain AV, Morales M, Lerma J. Selective antagonism of AMPA receptors unmasks kainate receptor-mediated responses in hippocampal neurons. Neuron 1995; 14: 185-189.
71. Wilding TJ, Huettner JE. Antagonist pharmacology of kainate- and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-preferring receptors. Mol Pharmacol 1996; 49: 540-546.
72. Lodge D, Jones MG, Palmer AJ. Excitatory amino acids: new tools for old stories of pharmacologica subtypes of glutamate receptors: electrophysiological studies. Can J Physiol Pharmacol 1991; 69: 1123-8.
73. Bortolotto ZA, Clarke VR, Delany CM, Parry MC, Smolders I, Vignes M, et al. Kainate receptors are involved in synaptic plasticity. Nature 1999; 402: 297-301.
74. Smolders I, Bortolotto ZA, Clarke VR, Warse R, Khan GM, O'Neill MJ, et al. Antagonists of Glu(K5)-containing kainite receptors prevent pilocarpine-induced limbic seizures. Nat Neurosci 2002; 5: 796-804.
75. Wong LA, Mayer ML, Jane DE, Watkins JC. Willardiines differentiate agonist binding sites for kainate- versus AMPA-preferring glutamate receptors in DRG and hippocampal neurons. J Neurosci 1994; 14: 3881-97.
76. Gu Z-Q, Hesson DP, Pelletier JC, Maccecchini ML, Zhou LM, Skolnick P. Synthesis, resolution, and biological evaluation of the four stereoisomers of 4-methylglutamic acid: selective probes of kainate receptors. J Med Chem 1995; 38: 2518-2520.
77. Donevan SD, Beg A, Gunther JM, Twyman RE. The methylglutamate, SYM 2081, is a potent and highly selective agonist at kainate receptors. J Pharmacol Exp Ther 1998; 285: 539-545.
78. Jones KA, Wilding TJ, Huettner JE, Costa AM. Desensitization of kainate receptors by kainate, glutamate and diasteroisomers of 4-methylglutamate. Neuropharmacology 1997; 36: 853-863.
79. Zhou L-M, Gu Z-Q, Costa AM, Yamada KA, Mansson PE, Giordano T, et al. (2S, 4R)-4-methylglutamic acid (SYM 2081): a selective, high-affinity ligand for kainate receptors. J Pharmacol Exp Ther 1997; 280: 422-427.
80. Li P, Wilding TJ, Kim SJ, Calejesan AA, Huettner JE, Zhuo M. Kainate-receptor-mediated sensory synaptic transmission in mammalian spinal cord. Nature 1999; 397: 161-164.
81. More JCA, Troop HM, Dolman NP, Jane DE. Structural requirements for novel willardiine derivatives acting as AMPA and kainate receptor antagonists. British J Pharmacol 2003; 138: 1093-1100.
82. More JCA, Dolman NP, Troop HM, Jane DE. Effect on AMPA and kainate receptor antagonist activity of changing the terminal acidic group of N3- substituted willardiine derivatives. B J of Pharmacol 2003; 139: 9.
83. Collingridge GL, Watkins TC. The NMDA receptor, Oxford University Press: Oxford, 1994.
84. Felsby S, Nielsen J, Arandt-Nielsen L, Jensen TS. NMDA receptor blockade in chronic neuropathic pain: a comparison of ketamine and magnesium chloride. Pain 1996; 64: 283.
85. Loftis JM, Janowsky A. The N-methyl-D-aspartate receptor subunit NR2B: localization, functional properties, regulation, and clinical implications. Pharmacol Ther 2003, 97: 55-85.
86. Forrest D, Yuzaki M, Soares HD, Ng L, Luk DC, Sheng M, et al. Targeted disruption of NMDA receptor 1 gene abolishes NMDA response and results in neonatal death. Neuron 1994; 13: 325.
87. Li Y, Erzurumlu R, Chen C, Jhaveri S, Tonegawa S. Whisker-related neuronal patterns fail to develop in the trigeminal brainstem nuclei of NMDAR1 knockout mice. Cell 1994; 76: 427.
88. Mohn AR, Gainetdinov RR, Caron MG, Koller BH. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 1999; 98: 427-36.
89. Ikeda K, Araki K, Takayama C, Inoue Y, Yagi T, Aizawa S, et al. Reduced spontaneous activity of mice defective in the epsilon 4 subunit of the NMDA receptor channel. Brain Res Mol Brain Res 1995; 33: 61-71.
90. Kutsuwada T, Sakimura K, Manabe T, Takayama C, Katakura N, Kushiya E, et al. Impairment of suckling response, trigeminal neuronal pattern formation, and hippocampal LTD in NMDA receptor epsilon 2 subunit mutant mice. Neuron 1996; 16: 333-44.
91. Sakimura K, Kutsuwada T, Ito I, Manabe T, Takayama C, Kushiya E, et al. Reduced hippocampal LTP and spatial learning in mice lacking NMDA receptor epsilon 1 subunit. Nature 1995; 373: 151-5.
92. Ebralidze AK, Rossi DJ, Tonegawa S, Slater NT. J. Modification of NMDA receptor channels and synaptic transmission by targeted disruption of the NR2C gene. J Neurosci 1996; 16: 5014-25.
93. Das S, Sasaki YF, Rothe T, Premkumar YF, Takasu M, Crandall JE, et al. Increased NMDA current and spine density in mice lacking the NMDA receptor subunit NR3A. Nature 1998; 393: 377-81.
94. Planells-Cases R, Pérez-Payá E, Messeguer A, Carreño C, Ferrer-Montiel A. Small molecules targeting the NMDA receptor complex as drugs for neuropathic pain. Mini Rev Med Chem 2003; 3: 749-56.
95. Jane DE, Olverman HI, Watkins JC. Agonists and competitive antagonists: Structure, activity and molecular modelling studies. In: Collingridge GL, Watkins TC. The NMDA receptor, Oxford University Press: Oxford, 1994; pp. 31.
96. Meldrum BS, Chapman AG. In: Collingridge GL, Watkins TC. Competitive NMDA antagonists as drugs. The NMDA receptor, Oxford University Press: Oxford, 1994; pp. 457.
97. Danysz W, Parsons AC. Glycine and N-methyl-D-aspartate receptors: physiological significance and possible therapeutic applications. Pharmacol Rev 1998; 50: 597-664.
98. Lerma J, Zukin RS, Bennett MV. Glycine decreases desensitization of N-methyl-D-aspartate (NMDA) receptors expressed in Xenopus oocytes and is required for NMDA responses. Proc Natl Acad Sci USA 1990; 87: 2354-8.
99. Iversen LL, Kemp JA In: Collingridge GL, Watkins TC, Non-competitive NMDA antagonists as drugs. The NMDA receptor, Oxford University Press: Oxford, 1994; pp. 467.
100. Singh L, Donald AE, Foster AC, Hutson PH, Iversen LL, Kemp JA, et al. Enantiomers of HA-966 (3-amino-1-hydroxypyrolid-2-one) exhibit distinct central nervous system effects: (+)-HA-966 is a selective glycine/ N-methyl-D-aspartate receptor antagonist, but (-)-HA-966 is a potent gamma-butyrolactone-like sedative. Proc Natl Acad Sci USA 1990; 87: 347-51.
101. Parsons CG, Danysz W, Quack G, Hartmann S, Lorenz B, Wollenburg C, et al. Novel systemically active antagonists of the glycine site of the N-methyl-D-aspartate receptor: electrophysiological, biochemical and behavioral characterization. J Pharmacol Exp Ther 1997; 283: 1264-75.
102. Parsons, C.G. NMDA receptors as targets for drug action in neuropathic pain. Eur J Pharmacol 2001; 429: 71-8.
103. Chen L, Huang L-Y M. Dynorphin block of N-methyl-D-aspartate channels increases with the peptide length. J Pharmacol Exp Ther 1998; 284: 826-31.
104. Hauser KF, Knapp PE, Turbek CS. Structure-activity analysis of dynorphin A toxicity in spinal cord neurons: intrinsic neurotoxicity of dynorphin A and its carboxyl-terminal, nonopioid metabolites. Exp Neurol 2001; 168: 78-87.
105. Ferer-Montiel AV, Merino JM, Blondelle SE, Pérez-Payá E, Houghten RA, Montal M. Selected peptides targeted to the NMDA receptor channel protect neurons from excitotoxic death. Nat Biotechnol 1998; 16: 286-91.
106. Laughlin TM, Larson AA, Wilcox GL. Mechanisms of induction of persistent nociception by dynorphin. J Pharmacol Exp Ther 2001; 299: 6-11.
107. Tan-No K, Esashi A, Nakagawasai O, Niijima F, Tadano T, Sakurada C, et al. Intrathecally administered big dynorphin, a prodynorphin-derived peptide, produces nociceptive behavior through an N-methyl-D-aspartate receptor mechanism. Brain Res 2002: 952: 7-14.
108. Zhan RZ, Fujiwara N, Yamakura T, Taga K, Fukuda S, Endoh H, et al. NMDA induces a biphasic change in intracellular pH in rat hippocampal slices. Brain Res 1997; 760: 179-86.
109. Castellino FJ, Prorok M. Conantokins: inhibitors of ion flow through the N-methyl-D-aspartate receptor channels. Curr Drug Targets 2000; 1: 219-35.
110. Klein RC, Warder SE, Galdzicki Z, Castellino FJ, Prorok M. Kinetic and mechanistic characterization of NMDA receptor antagonism by replacement and truncation variants of the conantokin peptides. Neuropharmacology 2001; 41: 801-10.
111. Malmberg AB, Gilbert H, McCabe RT, Basbaum AI. Powerful antinociceptive effects of the cone snail venom-derived subtype-selective NMDA receptor antagonists conantokins G and T. Pain 2003; 101: 109-16.
112. Garry EM, Moss A, Delaney A, O'Neill F, Blakemore J, Bowen J, et al. Neuropathic sensitization of behavioral reflexes and spinal NMDA receptor/CaM kinase II interactions are disrupted in PSD-95 mutant mice. Curr Biol 2003; 13: 321-8.
113. Mealing GA, Lanthorn TH, Small DL, Murray RJ, Mattes KC, Comas TM, et al. Structural modifications to an N-methyl-D-aspartate receptor antagonist result in large differences in trapping block. J Pharmacol Exp Ther 2001; 297: 906-14.
114. Tai K-K, Blondelle S, Ostresh JM, Houghten RA, Montal M. An N-methyl-D-aspartate receptor channel blocker with neuroprotective activity. Proc Natl Acad Sci USA 2001; 98: 3519-24.
115. Planells-Cases R, Montoliu C, Humet C, Fernández A, García-Martínez C, Valera E, et al. A novel N-methyl-D-aspartate receptor open channel blocker with in vivo neuroprotectant activity. J Pharmacol Exp Ther 2002; 302: 163-73.
116. Miller SM, Simon RJ, Ng S, Zuckermann R, Kerr JM, Moss WH. Proteolytic studies of homologous peptides and N-substituted glycine peptoide oligomers. Bioorg and Med Chem Lett 1994; 4: 2657-62.
117. Simon RJ, Kania RS, Zuckermann RN, Verena D, Huebner VD, Jewell DA, et al. Peptoids: a modular approach to drug discovery. Proc Natl Acad Sci USA 1992; 89: 9367-71.
118. Ikonomidou C, Bosch F, Miksa M, Bittigan P, Vockler J, Dikranian K, et al. Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain. Science 1999; 283: 70-4.
119. Ikonomidou C, Stefovska V, Turski L. Neuronal death enhanced by N-methyl-D-aspartate antagonists. Proc Natl Acad Sci USA 2000; 97: 12885-90.
120. Ma QP, Hargreaves RJ. Localization of N-methyl-D-aspartate NR2B subunits on primary sensory neurons that give rise to small-caliber sciatic nerve fibers in rats. Neuroscience 2000; 101: 699-707.
121. Kew JN, Kemp JA. An allosteric interaction between the NMDA receptor polyamine and ifenprodil sites in rat cultured cortical neurones. J Physiol 1998; 512: 17-28.
122. Mott DD, Doherty JJ, Zhang S, Washburn MS, Fendley MJ, Lyuboslavsky P, et al. Phenylethanolamines inhibit NMDA receptors by enhancing proton inhibition. Nat Neurosci 1998; 1: 659-67.
123. During MJ, Symes CW, Lawlow PA, Lin J, Dunning J, Fizsimons HL, et al. An oral vaccine against NMDAR1 with efficacy in experimental stroke and epilepsy. Science 2000; 287: 1453-60.
124. Husi H, Ward MA, Choudhary JS, Blackstock WP, Grant SG. Proteomic analysis of NMDA receptor-adhesion protein signalling complexes. Nat Neurosci 2000; 3: 661-9.
125. Aarts M, Liu Y, Liu L, Besshoh S, Arundine M, Gurd JW, et al. Treatment of ischemic brain damage by perturbing NMDA receptor- PSD-95 protein interactions. Science 2002; 298: 846-50.
126. Lipton SA. Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders. J Azheimers Dis 2004; 6: S61-74.
127. Sonkusare SK, Laul CL, Ramarao P. Dementia of Alzheimer's disease and other neurodegenerative disorders-memantine, a new hope. Pharmacol Res 2005; 51: 1-17.
128. Kornhuber J, Quack G. Cerebrospinal fluid and serum concentrations of the N-methyl-D-aspartate (NMDA) receptor antagonist memantine in man. Neurosci Lett 1995; 195: 137-9.
129. Armijo JA, Shushtarian M, Valdizan EM, Cuadrado A, de las Cuevas I, Adin J. Ion channels and epilepsy. Curr Pharm Des 2005; 11(15): 1975-2003.
130. Chizh BA, Headley PM. NMDA antagonists and neuropathic pain-multiple drug targets and multiple uses. Curr Pharm Des 2005; 11(23): 2977-94.
131. de Bartolomeis A, Fiore G, Iasevoli F. Dopamine-glutamate interaction and antipsychotics mechanism of action: implication for new pharmacological strategies in psychosis. Curr Pharm Des 2005; 11(27): 3561-94.